Literature DB >> 26601803

Pharmacological exploration of the resting membrane potential reserve: Impact on atrial fibrillation.

Marcel A G van der Heyden1, Thomas Jespersen2.   

Abstract

The cardiac action potential arises and spreads throughout the myocardium as a consequence of highly organized spatial and temporal expression of ion channels conducting Na(+), Ca(2+) or K(+) currents. The cardiac Na(+) current is responsible for the initiation and progression of the action potential. Altered Na(+) current has been found implicated in a number of different arrhythmias, including atrial fibrillation. In the atrium, the resting membrane potential is more depolarized than in the ventricles, and as cardiac Na(+) channels undergo voltage-dependent inactivation close to this potential, minor changes in the membrane potential have a relatively large impact on the atrial Na(+) current. The atrial resting membrane potential is established following ionic currents through the inwardly rectifying K(+) currents IK1, IK,ACh and IK,Ca and to a lesser extent by other ion channels as well as by exchangers and pumps. This review will focus on the relative and regulated contribution of IK1, IK,ACh and IK,Ca, and on pharmacological modification of the channels underlying these currents in respect to the resting membrane potential, Na(+) channel availability and atrial electrophysiology in health and disease.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; I(K,ACh); I(K,Ca); I(K1); I(Na); Resting membrane potential

Mesh:

Substances:

Year:  2015        PMID: 26601803     DOI: 10.1016/j.ejphar.2015.11.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  The inward rectifier current inhibitor PA-6 terminates atrial fibrillation and does not cause ventricular arrhythmias in goat and dog models.

Authors:  Yuan Ji; Rosanne Varkevisser; Dragan Opacic; Alexandre Bossu; Marion Kuiper; Jet D M Beekman; Sihyung Yang; Azinwi Phina Khan; Dobromir Dobrev; Niels Voigt; Michael Zhuo Wang; Sander Verheule; Marc A Vos; Marcel A G van der Heyden
Journal:  Br J Pharmacol       Date:  2017-06-28       Impact factor: 8.739

2.  Electrophysiologic effects of the IK1 inhibitor PA-6 are modulated by extracellular potassium in isolated guinea pig hearts.

Authors:  Gregory S Hoeker; Mark A Skarsfeldt; Thomas Jespersen; Steven Poelzing
Journal:  Physiol Rep       Date:  2017-01-13

3.  Quantitative Analysis of the Cytoskeleton's Role in Inward Rectifier K IR 2.1 Forward and Backward Trafficking.

Authors:  Encan Li; Vera Loen; Willem B van Ham; Willy Kool; Marcel A G van der Heyden; Hiroki Takanari
Journal:  Front Physiol       Date:  2022-01-25       Impact factor: 4.566

4.  Glycogen synthase kinase 3 beta inhibitor SB216763 improves Kir2.1 expression after myocardia infraction in rats.

Authors:  Cheng Chang; Shu-Hui Wang; Li-Na Xu; Xue-Ling Su; Yi-Fan Zeng; Peng Wang; Li-Rong Zhang; Sheng-Na Han
Journal:  J Interv Card Electrophysiol       Date:  2021-02-20       Impact factor: 1.900

5.  Pharmacological inhibition of IK1 by PA-6 in isolated rat hearts affects ventricular repolarization and refractoriness.

Authors:  Mark A Skarsfeldt; Helena Carstensen; Lasse Skibsbye; Chuyi Tang; Rikke Buhl; Bo H Bentzen; Thomas Jespersen
Journal:  Physiol Rep       Date:  2016-04

6.  Efficacy of pentamidine analogue 6 in dogs with chronic atrial fibrillation.

Authors:  Viktor Szatmári; Yuan Ji; Bianca van Herwijnen; Mei Feng; Michael Zhou Wang; Alexandre Bossu; Marcel A G van der Heyden
Journal:  J Vet Intern Med       Date:  2018-08-05       Impact factor: 3.333

Review 7.  Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease.

Authors:  Laura van der Schoor; Emma J van Hattum; Sophie M de Wilde; Netanja I Harlianto; Aart-Jan van Weert; Meye Bloothooft; Marcel A G van der Heyden
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.